Drug delivery to the posterior segment of the eye

Drug Discovery Today

Volumn 16, Issue 5-6, 2011, Pages 270-277

  Thrimawithana, Thilini Rasika ^a   Young, Simon ^a   Bunt, Craig Robert ^b   Green, Colin ^a   Alany, Raid Ghassan ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AGRESEARCH LTD   (New Zealand)

^c KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE TRANSFORMING GROWTH FACTOR BETA 2 PHOSPHOROTHIOATE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BETAMETHASONE; BUDESONIDE; CELECOXIB; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; DENDRIMER PORPHYRIN; DEXAMETHASONE; ETACRYNIC ACID; EYEGATE; FLUOCINOLONE ACETONIDE; FLUORESCEIN; FLUOROURACIL; FOMIVIRSEN; GANCICLOVIR; ILLUVIEN; IMMUNOGLOBULIN G; IVATION; MEDIDUR; MIDOSTAURIN; OCUPHOR; OLIGONUCLEOTIDE; PEGAPTANIB; PEPTIDE APTAMER; PILOCARPINE; PORPHYRIN DERIVATIVE; RNA APTAMER; STEROID; SULFORHODAMINE B; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN; VISULEX;

ANTERIOR EYE CHAMBER; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CATARACT; CHRONIC NONINFECTIOUS UVEITIS; CLINICAL TRIAL (TOPIC); DIABETIC RETINOPATHY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG STABILITY; EYE; GENE DELIVERY SYSTEM; GLAUCOMA; HUMAN; IMPLANT; INJECTION; INTRAOCULAR HYPERTENSION; IONTOPHORESIS; LIGHT; MICRONEEDLE; NANOENCAPSULATION; NEEDLE; NONHUMAN; POSTERIOR EYE SEGMENT; RABBIT; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINITIS; RETINITIS PIGMENTOSA; RETINOBLASTOMA; REVIEW; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VITREOUS HEMORRHAGE;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-RETINAL BARRIER; DRUG DELIVERY SYSTEMS; EYE; EYE DISEASES; HUMANS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SCLERA;

EID: 79952450877     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.12.004     Document Type: Review

References (97)

1. K.G. Janoria Novel approaches to retinal drug delivery Expert Opin. Drug Deliv. 4 2007 371 388 (Pubitemid 47260195)
2. I.P. Kaur, and M. Kanwar Ocular preparations: the formulation approach Drug Dev. Ind. Pharm. 28 2002 473 493 (Pubitemid 34680549)
3. A. Urtti, and E.M. Del Amo Current and future ophthalmic drug delivery systems - a shift to the posterior segment Drug Discov. Today 13 2008 135 143
4. P.M. Hughes Topical and systemic drug delivery to the posterior segments Adv. Drug Deliv. Rev. 57 2005 2010 2032 (Pubitemid 41740793)
5. S. Duvvuri Drug delivery to the retina: challenges and opportunities Expert Opin. Biol. Ther. 3 2003 45 56 (Pubitemid 36193650)
6. J. Hsu Drug delivery methods for posterior segment disease Curr. Opin. Ophthalmol. 18 2007 235 239 (Pubitemid 46624923)
7. G.A. Peyman Intravitreal injection of therapeutic agents Retina 29 2009 875 912
8. H. Wu, and T.C. Chen The effects of intravitreal ophthalmic medications on intraocular pressure Semin. Ophthalmol. 24 2009 100 105
9. B.R. Conway Recent patents on ocular drug delivery systems Recent Pat. Drug Deliv. Formul. 2 2008 1 8 (Pubitemid 351546429)
10. A. Laude Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics Prog. Retin. Eye Res. 29 2010 466 475
11. D. Maurice Review: practical issues in intravitreal drug delivery J. Ocul. Pharmacol. Ther. 17 2001 393 401 (Pubitemid 32888812)
12. T.C. Prager The influence of vitreous change on vitreous fluorophotometry Arch. Ophthalmol. 100 1982 594 596 (Pubitemid 12136063)
13. D.M. Maurice The use of fluorescein in ophthalmological research Invest. Ophthalmol. 6 1967 464 477
14. D. Dalkara Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous Mol. Ther. 17 2009 2096 2102
15. M. Hornof Cell culture models of the ocular barriers Eur. J. Pharm. Biopharm. 60 2005 207 225 (Pubitemid 40804562)
16. N.P.S. Cheruvu Retinal delivery of sodium fluorescein, budesonide, and celecoxib following subconjunctival injection Drug Deliv. Technol. 3 2003 62 67
17. S. Raghava Periocular routes for retinal drug delivery Expert Opin. Drug Deliv. 1 2004 99 114 (Pubitemid 40297959)
18. J. Ambati, and A.P. Adamis Transscleral drug delivery to the retina and choroid Prog. Retin. Eye Res. 21 2002 145 151 (Pubitemid 34607434)
19. T.W. Olsen Human sclera: thickness and surface area Am. J. Ophthalmol. 125 1998 237 241 (Pubitemid 28081303)
20. T.W. Olsen Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning Invest. Ophthalmol. Vis. Sci. 36 1995 1893 1903
21. O.A. Boubriak The effect of hydration and matrix composition on solute diffusion in rabbit sclera Exp. Eye Res. 71 2000 503 514
22. D.E. Rudnick The effect of intraocular pressure on human and rabbit scleral permeability Invest. Ophthalmol. Vis. Sci. 40 1999 3054 3058 (Pubitemid 29521626)
23. S-B. Lee Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems Exp. Eye Res. 78 2004 599 607 (Pubitemid 38183339)
24. D. Ghate, and H.F. Edelhauser Ocular drug delivery Expert Opin. Drug Deliv. 3 2006 275 287 (Pubitemid 43338097)
25. D. Ghate Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry Invest. Ophthalmol. Vis. Sci. 48 2007 2230 2237 (Pubitemid 351261299)
26. O. Weijtens Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection Am. J. Ophthalmol. 123 1997 358 363 (Pubitemid 27123042)
27. O. Weijtens High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection Am. J. Ophthalmol. 128 1999 192 197 (Pubitemid 29379772)
28. V.P. Ranta, and A. Urtti Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling Adv. Drug Deliv. Rev. 58 2006 1164 1181
29. K.G. Janoria Novel approaches to retinal drug delivery Expert Opin. Drug Deliv 4 2007 371 388 (Pubitemid 47260195)
30. K.M. Hamalainen Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera Invest. Ophthalmol. Vis. Sci. 38 1997 627 634 (Pubitemid 27143133)
31. J. Ambati Diffusion of high molecular weight compounds through sclera Invest. Ophthalmol. Vis. Sci. 41 2000 1181 1185 (Pubitemid 30187558)
32. L. Pitkanen Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity Invest. Ophthalmol. Vis. Sci. 46 2005 641 646 (Pubitemid 40270347)
33. J. Ambati Transscleral delivery of bioactive protein to the choroid and retina Invest. Ophthalmol. Vis. Sci. 41 2000 1186 1191 (Pubitemid 30187559)
34. M.F. Marmor Kinetics of macromolecules injected into the subretinal space Exp. Eye Res. 40 1985 687 696 (Pubitemid 16161524)
35. D.H. Geroski, and H.F. Edelhauser Transscleral drug delivery for posterior segment disease Adv. Drug Deliv. Rev. 52 2001 37 48 (Pubitemid 32973637)
36. A. Tsuji Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits Opthalmic Res. 20 1988 31 43 (Pubitemid 18090337)
37. H. Kim Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging Invest. Ophthalmol. Vis. Sci. 45 2004 2722 2731 (Pubitemid 38998870)
38. J.M. Conrad, and J.R. Robinson Mechanisms of anterior segment absorption of pilocarpine following subconjunctival injection in albino rabbits J. Pharm. Sci. 69 1980 875 884 (Pubitemid 11234571)
39. P.K. Kaiser Posterior juxtascleral depot administration of anecortave acetate Surv. Ophthalmol. 52 Suppl. 1 2007 S62 S69
40. J.A. Gilbert Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix J. Control. Release 89 2003 409 417 (Pubitemid 36555900)
41. A. Bill Movement of albumin and dextran through the sclera Arch. Ophthalmol. 74 1965 248 252
42. A.C. Amrite Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration Mol. Vis. 14 2008 150 160 (Pubitemid 351194002)
43. M.R. Robinson A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide Exp. Eye Res. 82 2006 479 487 (Pubitemid 43138962)
44. S.H. Kim Transport barriers in transscleral drug delivery for retinal diseases Ophthalmic Res. 39 2007 244 254 (Pubitemid 47557244)
45. J. Barar Ocular novel drug delivery: impacts of membranes and barriers Expert Opin. Drug Deliv. 5 2008 567 581 (Pubitemid 351877434)
46. E. Mannermaa Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics Adv. Drug Deliv. Rev. 58 2006 1136 1163
47. J.G. Cunha-Vaz The blood-retinal barriers system. Basic concepts and clinical evaluation Exp. Eye Res. 78 2004 715 721 (Pubitemid 38183350)
48. L. Pitkanen Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium Pharm. Res. 24 2007 2063 2070 (Pubitemid 47493576)
49. A.M. Demetriades Trans-scleral delivery of antiangiogenic proteins J. Ocul. Pharmacol. Ther. 24 2008 70 79 (Pubitemid 351156635)
50. D.L. Becker Pluronic gel as a means of antisense delivery R.A. Leslie, Antisense Technology for the Central Nervous System 1999 Oxford University Press 149 157
51. J.L. Bourges Intraocular implants for extended drug delivery: therapeutic applications Adv. Drug Deliv. Rev. 58 2006 1182 1202 (Pubitemid 44794429)
52. D.C. Musch Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group N. Engl. J. Med. 337 1997 83 90 (Pubitemid 27284393)
53. G.J. Jaffe Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis, thirty-four-week results of a multicenter randomized clinical study Ophthalmology 113 2006 1020 1027 (Pubitemid 43795240)
54. F.E. Kane Iluvien™: a new sustained delivery technology for posterior eye disease Expert Opin. Drug Deliv. 5 2008 1039 1046
55. N. Kuno, and S. Fujii Biodegradable intraocular therapies for retinal disorders: progress to date Drugs Aging 27 2010 117 134
56. A. Kato Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant Invest. Ophthalmol. Vis. Sci. 45 2004 238 244 (Pubitemid 38055693)
57. R.A. Pontes de Carvalho Delivery from episcleral exoplants Invest. Ophthalmol. Vis. Sci. 47 2006 4532 4539 (Pubitemid 46579382)
58. A.A. Moshfeghi, and G.A. Peyman Micro- and nanoparticulates Adv. Drug Deliv. Rev. 57 2005 2047 2052 (Pubitemid 41740795)
59. Y. Saishin Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model Invest. Ophthalmol. Vis. Sci. 44 2003 4989 4993 (Pubitemid 37315317)
60. A.L. Gomes dos Santos Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta2 oligonucleotide improves the outcome of glaucoma surgery J. Control. Release 112 2006 369 381
61. A.L. Gomes dos Santos Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy Pharm. Res. 23 2006 770 781
62. J-L. Bourges Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles Invest. Ophthalmol. Vis. Sci. 44 2003 3562 3569 (Pubitemid 36909796)
63. R.A. Bejjani Nanoparticles for gene delivery to retinal pigment epithelial cells Mol. Vis. 11 2005 124 132 (Pubitemid 41358300)
64. R.M. Mainardes Colloidal carriers for ophthalmic drug delivery Curr. Drug Targets 6 2005 363 371 (Pubitemid 40667801)
65. J.G. Christie, and U.B. Kompella Ophthalmic light sensitive nanocarrier systems Drug Discov. Today 13 2008 124 134
66. E.M. del Amo, and A. Urtti Current and future ophthalmic drug delivery systems. A shift to the posterior segment Drug Discov. Today 13 2008 135 143
67. R. Zeimer, and M.F. Goldberg Novel ophthalmic therapeutic modalities based on noninvasive light-targeted drug delivery to the posterior pole of the eye Adv. Drug Deliv. Rev. 52 2001 49 61 (Pubitemid 32973638)
68. R. Ideta Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer Nano Lett. 5 2005 2426 2431 (Pubitemid 43088890)
69. N. Normand VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo Mol. Vis. 11 2005 184 191 (Pubitemid 41358293)
70. L. Paasonen Gold nanoparticles enable selective light-induced contents release from liposomes J. Control. Release 122 2007 86 93 (Pubitemid 47284557)
71. A. Suzuki, and T. Tanaka Phase transition in polymer gels induced by visible light Nature 346 1990 345 347
72. N. Yui Photo-responsive degradation of heterogeneous hydrogels comprising crosslinked hyaluronic acid and lipid microspheres for temporal drug delivery J. Control. Release 26 1993 141 145 (Pubitemid 23226019)
73. D. Sarraf, and D.A. Lee The role of iontophoresis in ocular drug delivery J. Ocul. Pharmacol. 10 1994 69 81 (Pubitemid 24119431)
74. S.A. Molokhia Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI Exp. Eye Res. 88 2009 418 425
75. E. Eljarrat-Binstock, and A.J. Domb Iontophoresis: a non-invasive ocular drug delivery J. Control. Release 110 2006 479 489 (Pubitemid 43163439)
76. J.B. Davies Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields Mol. Vis. 9 2003 569 578 (Pubitemid 38097624)
77. T.T. Lam A histopathological study of retinal lesions inflicted by transcleral iontophoresis Graefes Arch. Clin. Exp. Ophthalmol. 229 1991 389 394
78. T.M. Parkinson Tolerance of ocular iontophoresis in healthy volunteers J. Ocul. Pharmacol. Ther. 19 2003 145 151 (Pubitemid 36539140)
79. M. Halhal Iontophoresis: from the lab to the bed side Exp. Eye Res. 78 2004 751 757 (Pubitemid 38183354)
80. J. Jiang Intrascleral drug delivery to the eye using hollow microneedles Pharm. Res. 26 2009 395 403
81. J. Okabe Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate Invest. Ophthalmol. Vis. Sci. 44 2003 740 744 (Pubitemid 36159723)
82. Y. Wang Controlled release of ethacrynic acid from poly(lactide-co- glycolide) films for glaucoma treatment Biomaterials 25 2004 4279 4285 (Pubitemid 38388589)
83. M. Zignani A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release Eur. J. Pharm. Biopharm. 50 2000 251 255
84. D.F. Emerich, and C.G. Thanos NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells Curr. Opin. Mol. Ther. 10 2008 506 515
85. R. Russell Bioerodable eye implant may help treat macular edema Pharma. Technol. 28 2004 18 + 223
86. J.L. Marx Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis Arch. Ophthalmol. 114 1996 815 820 (Pubitemid 26240528)
87. J.A. Montero, and J.M. Ruiz-Moreno Intravitreal inserts of steroids to treat diabetic macular edema Curr. Diabetes Rev. 5 2009 26 32
88. S.S. Lee, and M.R. Robinson Novel drug delivery systems for retinal diseases: a review Ophthalmic Res. 41 2009 124 135
89. S. Ebrahim Applications of liposomes in ophthalmology Surv. Ophthalmol. 50 2005 167 182 (Pubitemid 40340948)
90. R.Z. Renno, and J.W. Miller Photosensitizer delivery for photodynamic therapy of choroidal neovascularization Adv. Drug Deliv. Rev. 52 2001 63 78 (Pubitemid 32973639)
91. T.W. Olsen Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment Am. J. Ophthalmol. 142 2006 777 787
92. S.P. Ayalasomayajula, and U.B. Kompella Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model Eur. J. Pharmacol. 511 2005 191 198 (Pubitemid 40417726)
93. K.G. Carrasquillo Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres Invest. Ophthalmol. Vis. Sci. 44 2003 290 299 (Pubitemid 36134287)
94. U.B. Kompella Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression Invest. Ophthalmol. Vis. Sci. 44 2003 1192 1201 (Pubitemid 36297840)
95. ®) for diabetic macular oedema Acta Ophthalmol. 87 2009 623 630
96. C.M. Perry, and J.A.B. Balfour Fomivirsen Drugs 57 1999 375 381 (Pubitemid 29137482)
97. M-E. Jockovich Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes Retina 27 2007 247 252